708 related articles for article (PubMed ID: 29167005)
1. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
2. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
3. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
4. Frequencies of PD-1- and PD-L1- positive T CD3
Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
[TBL] [Abstract][Full Text] [Related]
5. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
6. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
[TBL] [Abstract][Full Text] [Related]
7. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
[TBL] [Abstract][Full Text] [Related]
8. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract][Full Text] [Related]
9. Immunoregulatory molecules in patients with gestational diabetes mellitus.
Pendeloski KP; Mattar R; Torloni MR; Gomes CP; Alexandre SM; Daher S
Endocrine; 2015 Sep; 50(1):99-109. PubMed ID: 25754913
[TBL] [Abstract][Full Text] [Related]
10. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
11. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
[TBL] [Abstract][Full Text] [Related]
12. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
[TBL] [Abstract][Full Text] [Related]
13. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
15. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
[TBL] [Abstract][Full Text] [Related]
16. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis.
Rabe H; Nordström I; Andersson K; Lundell AC; Rudin A
Immunology; 2014 Mar; 141(3):467-81. PubMed ID: 24708420
[TBL] [Abstract][Full Text] [Related]
17. CD25-expressing Th17 cells mediate CD8
Lang C; Wang J; Chen L
Exp Cell Res; 2017 Nov; 360(2):384-389. PubMed ID: 28942020
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
[TBL] [Abstract][Full Text] [Related]
19. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.
Goto M; Chamoto K; Higuchi K; Yamashita S; Noda K; Iino T; Miura M; Yamasaki T; Ogawa O; Sonobe M; Date H; Hamanishi J; Mandai M; Tanaka Y; Chikuma S; Hatae R; Muto M; Minamiguchi S; Minato N; Honjo T
Sci Rep; 2019 Jul; 9(1):10144. PubMed ID: 31300681
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
